|
2024
|
Invention
|
T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t ... |
|
|
Invention
|
Bispecific chimeric antigen receptors and use thereof. The present disclosure relates to bispecif... |
|
|
Invention
|
Methods for making, compositions comprising, and methods of using rejuvenated t cells.
The prese... |
|
|
Invention
|
Methods for culturing immune cells. The preset disclosure provides methods of culturing TILs by f... |
|
|
Invention
|
Il-12 stability variants. The present disclosure provides IL-12 stability variants, nucleic acids... |
|
|
Invention
|
Novel recombinant cell surface markers.
The present disclosure relates to EGFR-derived polypepti... |
|
|
Invention
|
Methods of culturing reprogrammed cells. The present disclosure provides methods of culturing rep... |
|
|
Invention
|
Targeted il-12 affinity variants. The present disclosure provides targeted IL-12 affinity variant... |
|
2023
|
Invention
|
Methods for culturing nr4a-deficient cells. e.g.e.g.e.g., to comprise a chimeric antigen receptor... |
|
|
Invention
|
Methods for culturing nr4a-deficient cells overexpressing c-jun. Disclosed herein are methods of ... |
|
|
Invention
|
Methods for culturing nr4a-deficient cells. Disclosed herein are methods of culturing immune cell... |
|
|
Invention
|
Methods of manufacturing chimeric antigen receptor t cells |
|
|
Invention
|
Immune cell therapy. The present disclosure provides compositions and methods for improving immun... |
|
|
Invention
|
Polynucleotides targeting nr4a3 and uses thereof |
|
|
Invention
|
Polynucleotides targeting nr4a3 and uses thereof. The present disclosure provides polynucleotides... |
|
|
Invention
|
Il-12 affinity variants. The present disclosure provides IL-12 affinity variants, pharmaceutical ... |
|
2022
|
Invention
|
Methods for culturing cells expressing ror1-binding protein.
Disclosed herein are methods of cul... |
|
|
Invention
|
Methods for culturing cells expressing c-jun.
Disclosed herein are methods of culturing immune c... |
|
|
Invention
|
Methods of generating cells.
The present disclosure provides methods of preparing immune cells, ... |
|
|
Invention
|
Methods for culturing cells expressing c-jun. Disclosed herein are methods of culturing immune ce... |
|
|
Invention
|
Methods of generating cells. The preset disclosure provides methods of preparing immune cells, e.... |
|
|
Invention
|
Enhanced t cell therapy targeting ny-eso-1. 157-165157-165157-165157-165/HLA-A*02 complex. |
|
|
Invention
|
Methods for culturing immune cells. The preset disclosure provides methods of culturing TILs in a... |
|
|
Invention
|
Methods for culturing cells expressing ror1-binding protein. Disclosed herein are methods of cult... |
|
|
Invention
|
Enhanced immune cell therapy.
The present disclosure provides engineered human cells (e.g., T ce... |
|
|
Invention
|
Enhanced immune cell therapy. The present disclosure provides engineered human cells (e.g., T cel... |
|
|
Invention
|
Nr4a-deficient cells expressing c-jun and uses thereof.
The present disclosure provides methods ... |
|
|
Invention
|
Nr4a3-deficient immune cells and uses thereof. The present disclosure provides methods of promoti... |
|
|
Invention
|
Nr4a-deficient cells expressing c-jun and uses thereof. The present disclosure provides met... |
|
|
G/S
|
Scientific and technological services and biological research and development relating thereto, n... |
|
|
Invention
|
Nr4a3-deficient immune cells and uses thereof.
The preset disclosure provides methods of promoti... |
|
|
Invention
|
Nr4a3-deficient immune cells and uses thereof. NR4A3e.gNR4A3NR4A3NR4A3 gene and/or NR4A3 protein ... |
|
|
Invention
|
Nr4a3-deficient cells and uses thereof. The preset disclosure provides methods of promoting... |
|
|
Invention
|
Enhanced immune cell therapy targeting ny-eso-1. The present application concerns engineered huma... |
|
|
Invention
|
Methods for culturing cells.
The preset disclosure provides methods of culturing cells, e.g., pl... |
|
|
Invention
|
Ror1 targeting chimeric antigen receptor. The present disclosure relates to polynucleotides encod... |
|
|
Invention
|
Codon-optimized nucleotide sequences encoding an ap-1 transcription factor. Disclosed herein are ... |
|
|
Invention
|
Methods for culturing cells. The preset disclosure provides methods of culturing cells, e.g., plu... |
|
|
Invention
|
Methods for culturing cells. e.g(e.g. e.g. e.g., to comprise a chimeric antigen receptor or an en... |
|
|
Invention
|
Improved immune cell therapy. The present disclosure provides engineered human cells (e.g., T cel... |
|
|
G/S
|
Chemical, biological and biochemical products for research and scientific purposes; reagents for ... |
|
|
G/S
|
Chemical, biological and biochemical products for research, scientific and medical purposes; reag... |
|
2021
|
Invention
|
Methods for culturing immune cells.
The preset disclosure provides methods of culturing TILs in ... |
|
|
Invention
|
Methods for making, compositions comprising, and methods of using rejuvenated t cells. The presen... |
|
|
G/S
|
Pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infe... |
|
|
Invention
|
Chimeric activation receptors.
The preset disclosure provides chimeric activation receptors comp... |
|
|
G/S
|
Custom manufacture of pharmaceuticals Pharmaceutical preparations and drugs for the treatment of ... |
|
2019
|
G/S
|
Pharmaceuticals preparations and drugs; pharmaceutical preparations and drugs for the treatment o... |
|
2018
|
G/S
|
Pharmaceutical preparations and drugs for the treatment of cancer; cells for medical or clinical ... |
